BioSig Technologies, Inc. (OTCQB: BSGM), is a medical device company that has developed a proprietary technology platform designed to improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP™ System. SNNLive spoke with Gregory D. Cash, President and CEO of BioSig Technologies, Inc. at the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Cash begins with an overview of the company, “BioSig is in the cardiac electrophysiology space. We work with helping to diagnose and provide treatment guidelines for rapid heart rhythms primarily Atrial Fibrillation, Ventricular Tachycardia.”
He discusses BioSig’s technology, “We are a plug-in to the existing cardiac electrophysiology recording system. We don’t have to displace products that are in there, but we help improve the signals they’re looking at for treatment.” He adds, “There’s about 20 million dollars’ worth of equipment in the typical cardiac electrophysiology lab, so you’ve got 60 cycle interference, you have electromagnetic interference and so that helps. It generates and obscures the signals that you are really looking for in order to treat them.” For more information, check out their website: www.BioSigTech.com
© 2017 Stock News Now
Supported by Superior Web Solutions